Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report)’s share price passed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $89.99 and traded as high as $93.42. Oruka Therapeutics shares last traded at $90.33, with a volume of 1,942,731 shares changing hands.
Key Headlines Impacting Oruka Therapeutics
Here are the key news stories impacting Oruka Therapeutics this week:
- Positive Sentiment: ORKA-001 produced complete skin clearance in 61% of patients receiving the 600 mg dose at Week 16 in the ongoing EVERLAST-B Phase 2b trial, while 86% achieved PASI 90. The company said results were consistent with the earlier EVERLAST-A study and that safety and tolerability remained favorable. Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001
- Positive Sentiment: The strong efficacy profile prompted analysts and market commentators to describe the treatment as potentially transformative for psoriasis. Guggenheim reportedly estimated that ORKA-001 could generate as much as $7 billion in peak sales, increasing the perceived upside of Oruka’s pipeline. Guggenheim ORKA-001 Peak Sales Estimate
- Positive Sentiment: Oruka expects to begin Phase 3 development of ORKA-001 in the first half of 2027. Additional catalysts include 52-week EVERLAST-A results expected in December 2026 and ORKA-002 Phase 2 psoriasis results expected in the first quarter of 2027. Oruka Therapeutics Stock Gains on Positive Trial Results
- Neutral Sentiment: A report listed short interest at zero shares with a zero-day days-to-cover ratio, suggesting short positioning is not currently a meaningful trading factor, although the data may be incomplete or inconsistently reported.
- Negative Sentiment: Oruka remains a clinical-stage biotechnology company with no approved product, so valuation depends heavily on future trial results, regulatory progress and financing needs. Reported insider activity also showed sales without purchases, which may weigh on investor sentiment.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on ORKA shares. Mizuho set a $120.00 price objective on Oruka Therapeutics in a research note on Thursday, September 3rd. Guggenheim reaffirmed a “buy” rating on shares of Oruka Therapeutics in a report on Monday. Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. UBS Group lifted their price target on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Oruka Therapeutics in a report on Wednesday, October 7th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $128.91.
Read Our Latest Stock Report on ORKA
Oruka Therapeutics Price Performance
The firm has a market cap of $5.98 billion, a price-to-earnings ratio of -44.50 and a beta of -0.37. The company has a fifty day moving average price of $89.99 and a two-hundred day moving average price of $67.22.
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). On average, research analysts expect that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current fiscal year.
Insider Activity
In other news, SVP Arjun Agarwal sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the transaction, the senior vice president owned 15,312 shares in the company, valued at approximately $1,633,177.92. This trade represents a 39.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total value of $734,143.86. Following the transaction, the insider owned 31,771 shares in the company, valued at approximately $2,935,004.98. This trade represents a 20.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 154,950 shares of company stock worth $14,102,680 in the last ninety days. Corporate insiders own 23.49% of the company’s stock.
Institutional Investors Weigh In On Oruka Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of Oruka Therapeutics during the 2nd quarter worth about $474,916,000. Jupiter Topco LLC bought a new stake in Oruka Therapeutics during the 2nd quarter valued at approximately $130,968,000. Bank of America Corp DE bought a new stake in Oruka Therapeutics during the 2nd quarter valued at approximately $33,578,000. Braidwell LP acquired a new stake in Oruka Therapeutics in the 2nd quarter valued at approximately $26,473,000. Finally, Atika Capital Management LLC acquired a new stake in Oruka Therapeutics in the 1st quarter valued at approximately $11,277,000. 56.44% of the stock is owned by institutional investors and hedge funds.
About Oruka Therapeutics
Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.
Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.
Read More
- Five stocks we like better than Oruka Therapeutics
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
